Indivior poised for growth in small-cap biotech with opioid disorder treatments

Name: Indivior poised for growth in small-cap biotech with opioid disorder treatments
Uploaded: 2025-12-19T19:46:28Z
Duration: 33 s

Making Money with Charles Payne · FBN · Dec 19, 2025 · 33sSign Up Now

Already a subscriber?

Kevin Mahn identifies Indivior (INDV) as a promising company in the "Small-Cap Biotech Merge Mania" theme. He explains that Indivior develops drugs for serious mental disorders and substance abuse, with two key drugs in the FDA approval pipeline for opioid disorders. Mahn anticipates that success in these treatments could lead to significant impact on public health and potential acquisition by larger pharmaceutical companies.